{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:08:14Z","timestamp":1777417694900,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"10","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2002,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report a case of rhabdomyolysis and acute hepatitis associated with the coadministration of atorvastatin and diltiazem.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 60-year-old African American man with a significant past medical history presented to the emergency department with acute renal failure secondary to rhabdomyolysis. In addition, liver enzymes were elevated to greater than 3 \u00d7 normal. The only change in medication was the initiation of diltiazem 3 weeks earlier for atrial fibrillation to a complicated medication regimen that included atorvastatin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Rhabdomyolysis has been reported in patients receiving hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors when coadministered with agents that may inhibit their metabolism. Atorvastatin is the most potent of this class of agents currently available and is commonly used in the treatment of hyperlipidemia. Rhabdomyolysis resulting from the drug interaction between diltiazem and other HMG-CoA reductase inhibitors has been described in the literature. However, no report has specifically associated this adverse event with atorvastatin and diltiazem. We describe a patient with a complex medication regimen who was admitted for rhabdomyolysis and accompanying acute renal failure, along with acute hepatitis, thought to be secondary to a drug interaction between atorvastatin and diltiazem.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>While optimizing the patient's lipid profile should be the primary factor in choosing one statin over another, the potential for drug interactions requires close attention. All patients beginning HMG-CoA reductase inhibitor therapy should be counseled regarding the signs and symptoms of muscle injury; particular attention should be paid to those patients who are taking medications that may interact.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1a481","type":"journal-article","created":{"date-parts":[[2003,6,4]],"date-time":"2003-06-04T16:06:13Z","timestamp":1054742773000},"page":"1546-1549","source":"Crossref","is-referenced-by-count":47,"title":["Rhabdomyolysis with Concurrent Atorvastatin and Diltiazem"],"prefix":"10.1177","volume":"36","author":[{"suffix":"III","given":"John J","family":"Lewin","sequence":"first","affiliation":[{"name":"John J Lewin III PharmD, at time of writing, Resident, Critical Care Pharmacy Practice, College of Pharmacy, Medical University of South Carolina, Charleston, SC; now, Clinical Specialist, Critical Care, University of Maryland Hospital, and Clinical Assistant Professor, University of Maryland College of Pharmacy, Baltimore, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M","family":"Nappi","sequence":"additional","affiliation":[{"name":"Jean M Nappi PharmD BCPS FCCP, Vice-Chair and Professor of Pharmacy, College of Pharmacy, Medical University of South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marian H","family":"Taylor","sequence":"additional","affiliation":[{"name":"Marian H Taylor MD, Cardiology Fellow, Department of Medicine, Medical University of South Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2002,10,1]]},"reference":[{"key":"bibr-bibr1-aph.1A481","unstructured":"Food and Drug Administration. Bayer voluntarily withdraws Baycol [cited 2001 Sep 28]. Available from: URL: http:\/\/www.fda.gov\/bbs\/topics\/ANSWERS\/2001\/ANS01095.html."},{"key":"bibr-bibr2-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.15.2273"},{"key":"bibr-bibr3-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1345\/aph.10228"},{"key":"bibr-bibr4-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(99)00045-5"},{"key":"bibr-bibr5-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450010075034"},{"key":"bibr-bibr6-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1345\/aph.19039"},{"key":"bibr-bibr7-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(97)00907-7"},{"key":"bibr-bibr8-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(01)01135-4"},{"key":"bibr-bibr9-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(00)00367-3"},{"key":"bibr-bibr10-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb03948.x"},{"key":"bibr-bibr11-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0098-2997(97)00014-9"},{"key":"bibr-bibr12-aph.1A481","first-page":"1281","volume":"16","author":"Herman R","year":"1999","journal-title":"Can Med Assoc J"},{"key":"bibr-bibr13-aph.1A481","first-page":"S437","volume":"13","author":"Yang BB","year":"1996","journal-title":"Pharm Res"},{"key":"bibr-bibr14-aph.1A481","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0009-9236(96)90167-8","volume":"60","author":"Kantola T","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"bibr-bibr15-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(85)90541-6"},{"key":"bibr-bibr16-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(98)90067-4"},{"key":"bibr-bibr17-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr-bibr18-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-198205000-00002"},{"key":"bibr-bibr19-aph.1A481","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(00)00946-2"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A481","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1A481","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:05:33Z","timestamp":1777374333000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1A481"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["10.1345\/aph.1A481"],"URL":"https:\/\/doi.org\/10.1345\/aph.1a481","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}